HARVARD BIOSCIENCE INC

Regulatory Filings • Apr 16, 2025

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K

Field: Rule-Page

Field: /Rule-Page

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 10, 2025

Field: Rule-Page

Field: /Rule-Page

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Field: Rule-Page

Field: /Rule-Page

Delaware	001-33957	04-3306140
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

84 October Hill Road

Holliston , MA 01746

(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	HBIO	The NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Page; Sequence: 1

Field: /Page

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 10, 2025, Bertrand Loy informed the Company that he will not stand for re-election at the Company’s 2025 Annual Meeting. Mr. Loy’s decision was not a result of any disagreement or any matter relating to the Company’s operations, policies, or practices.

Mr. Loy has served as a member of the Board since 2014 and currently serves as the Company’s Lead Independent Director and as a member of the Audit Committee and the Nominating and Governance Committee. Mr. Loy will continue to serve as a director and in such roles until the Company’s 2025 Annual Meeting. The Board expresses its appreciation to Mr. Loy for his service to the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit Number	Description
104	Cover Page Interactive Data File (embedded within the XBRL document)

Field: Page; Sequence: 2

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ John Fry
John Fry
Secretary

Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjd0KwjAMhZ9g7xB6PbSbP8judEwRp8gQ8ba6KMWtGWn9eyTf0rohhkBIzvlyhAjFgua6QobDrMhhh3VTKYdQ4BkZzQm9I12uEvCzwIu2jpVx7foDU/IMembck0d/b513bbFMQA770bgfj0BOkkEE07UIvnpK5qxLNE6rCpQpYcvUsEan+NV92KknGapfbdIe2WoyCUQ92clviGUUw4bu6kF8tZDnqQjCtgKxYLo13pU9HZovCVmFtY+zHf3v4APD8UpP